Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario
Renal cell carcinoma (RCC) represents the 12th most common cancer worldwide and the third most common newly diagnosed urogenital cancer after prostate cancer and urothelial carcinoma [1]. Standard treatment for localized non-metastatic RCC (stage I-III) is radical or partial nephrectomy. After radical surgery, patients with stage II-III have a substantial risk of relapse, which is estimated at around 35% [2,3]. The risk of disease recurrence is even greater in those patients who received resection of a metastatic lesion, a condition defined as “M1 with no evidence of disease (M1 NED)” [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 24, 2023 Category: Cancer & Oncology Authors: Chiara Ciccarese, Alessandro Strusi, Daniela Arduini, Pierluigi Russo, Giuseppe Palermo, Nazario Foschi, Marco Racioppi, Giampaolo Tortora, Roberto Iacovelli Tags: Anti-tumour Treatment Source Type: research
Epidemiology, Clinical Outcomes, and Unmet Needs of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: A Systematic Literature Review
Breast cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related death in women worldwide [1]. In 2020, there were approximately 2.3 million new cases of female breast cancer across the world (11.7% of all new cancer cases) and it was associated with 685,000 deaths (6.9% of all cancer-related deaths) [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 22, 2023 Category: Cancer & Oncology Authors: Volkmar M üller, Rupert Bartsch, Nancy U. Lin, Filippo Montemurro, Mark D. Pegram, Sara M. Tolaney Tags: Systematic or Meta-analysis Studies Source Type: research
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]
The authors regret, the author affiliation “IRCCS Istituto Ortopedico Rizzoli, University of Bologna, Via Pupilli, 1, 40136 Bologna, Italy” reported in the article is not correct. The correct affiliation, applicable to the following authors, is as updated above. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 14, 2023 Category: Cancer & Oncology Authors: J.Y. Blay, N. Hindi, J. Bollard, S. Aguiar, M. Angel, B. Araya, R. Badilla, D. Bernabeu, F. Campos, C.H.S. Caro-S ánchez, B. Carvajal, A. Carvajal Montoya, S. Casavilca-Zambrano, V. Castro-Oliden, M. Chacón, M. Clara, P. Collini, R. Correa Genoroso, F.D Tags: Corrigendum Source Type: research
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives
Prostate cancer (PC) is one of the most frequently diagnosed cancers and the second-leading cause of cancer death in adult males, globally [1]. Most PC related deaths are associated with metastatic widespread, a condition which can occur either at diagnosis (about 5-10% of cases) or after disease relapse following local treatments (radical prostatectomy and/or radiation therapy). PC may relapse as biochemical recurrence in absence of distant metastases, a condition also known as “biochemical failure”, mainly treated with salvage radiotherapy. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 14, 2023 Category: Cancer & Oncology Authors: Alfredo Berruti, Sergio Bracarda, Orazio Caffo, Enrico Cortesi, Rolando D'Angelillo, Marzia Del Re, Gaetano Facchini, Giovanni Pappagallo, Giuseppe Procopio, Roberto Sabbatini, Daniele Santini Tags: Anti-tumour Treatment Source Type: research
Incorporating Radioligand Therapy in Clinical Practice in the United States for Patients With Prostate Cancer
In 2022, there will be approximately 268 ,490 newly diagnosed PC patients and 34,500 deaths [1]. Advanced PC evolves to metastatic castration-resistant PC (mCRPC) [2,3], a lethal phenotype, which results in prostate cancer-specific mortality [4–14]. The 5-year survival rate for men diagnosed with metastatic PC between 2011 and 2017 wa s 31% [1], indicating that the development of therapies with novel mechanisms of action demonstrating an overall survival benefit and an acceptable safety profile is needed [5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 10, 2023 Category: Cancer & Oncology Authors: Jeremie Calais, Stephen M. Eulau, Linda Gardner, Ralph J. Hauke, Ayse T. Kendi, Neal D. Shore, Song Zhao Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 1, 2023 Category: Cancer & Oncology Source Type: research
Germline TP53 pathogenic variants and breast cancer: a narrative review
Breast cancer is the most common cancer diagnosis in women and the majority are considered sporadic cases [1]. Around 10% of breast malignancies are associated with a germline pathogenic variant in one of the breast cancer susceptibility genes and family history is often the telltale of an underlying inherited predisposition [2,3]. BRCA1 and BRCA2 pathogenic variants are responsible for less than half of the variants involved in increased breast cancer risk and pathogenic variants in multiple other breast cancer predisposing genes, including TP53, are responsible for the remaining [4 –6]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 30, 2023 Category: Cancer & Oncology Authors: Eva Blondeaux, Luca Arecco, Kevin Punie, Rossella Graffeo, Angela Toss, Carmine De Angelis, Lucia Trevisan, Giulia Buzzatti, Sabine C. Linn, Peter Dubsky, Mara Cruellas, Ann H. Partridge, Judith Balma ña, Shani Paluch-Shimon, Matteo Lambertini Tags: Tumour Review Source Type: research
Molecular aspects of brain metastases in breast cancer
Breast cancer (BC) is one of the most frequent causes of brain metastases (BM), with an estimated occurrence of approximately 5% in selected populations and up to 15 –30% in patients with stage IV disease [1–3]. Breast cancer brain metastases (BCBM) usually accompany extracranial metastases, and the number of extracranial metastatic sites is considered a risk factor for BM development [4]. The most common classification of BC types is based on the assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 using immunohistochemistry (IHC) and, for HER2, in...
Source: Cancer Treatment Reviews - January 27, 2023 Category: Cancer & Oncology Authors: Bart łomiej Tomasik, Michał Bieńkowski, Zuzanna Górska, Klaudia Gutowska, Paulina Kumięga, Jacek Jassem, Renata Duchnowska Tags: Laboratory-Clinic Interface Source Type: research
A Systematic Review of eHealth Technologies for Breast Cancer Supportive Care
Managing the long-term care of patients with high-burden chronic conditions is a major challenge facing global healthcare today. Cancer is one of the most common chronic diseases worldwide [1] with breast cancer being the most common cancer among women [2]. In 2020, over 2 million women worldwide were newly diagnosed with breast cancer [2]. Beyond the burden that breast cancer itself poses, patients may also experience other comorbidities [3 –5] requiring further support. Providing high quality supportive care to patients with breast cancer involves patient care management and providing relief from treatment side effects...
Source: Cancer Treatment Reviews - January 26, 2023 Category: Cancer & Oncology Authors: Bishal Gyawali, Meghan Bowman, Isobel Sharpe, Matthew Jalink, Siddhartha Srivastava, Don Thiwanka Wijeratne Tags: Systematic or Meta-analysis Studies Source Type: research
Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges
Non-small cell lung cancer (NSCLC) is a heterogeneous disease characterized by a broad spectrum of oncogenic driver alterations. Currently, targeted therapies are the standard treatment for most oncogene-driven patients [1]. However, not all oncogenic drivers, such as human epidermal growth factor receptor 2 (HER2), have approved targeted agents. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 26, 2023 Category: Cancer & Oncology Authors: Ying Yu, Yehao Yang, Hui Li, Yun Fan Tags: Anti-tumour Treatment Source Type: research
Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
Chemotherapy-induced nausea and vomiting (CINV) are common and distressing side effects. 70% to 80% of cancer patients receiving chemotherapy develop CINV; without appropriate therapy, the risk of developing CINV rises to 90% of patients with highly-emetogenic-chemotherapy (HEC) [1 –3]. CINV is linked with worse quality of Life, treatment compliance, malnutrition, and, cognitive disorders, with a potential impact on anti-cancer treatment efficacy [4–6]. The treatment goal for CINV should be to avoid the first occurrence of CINV. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 21, 2023 Category: Cancer & Oncology Authors: Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagn ì, Valeria Altamura, Giovanni Scambia, Gennaro Daniele Tags: General and Supportive Care Source Type: research
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: an Italian consensus paper and critical review
Triple-negative (TN) breast cancer (BC) definition relies on immunohistochemistry (IHC) and in situ hybridization (ISH) assessment and refers to the absence of hormone receptor (HR) expression (estrogen receptor [ER] and progesterone receptor [PgR] expression (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 6, 2023 Category: Cancer & Oncology Authors: F Miglietta, A Fabi, D Generali, MV Dieci, G Arpino, G Bianchini, S Cinieri, PF Conte, G Curigliano, M De Laurentis, L Del Mastro, S De Placido, A Gennari, F Puglisi, A Zambelli, F Perrone, V Guarneri Source Type: research
Management of Indolent B-cell Lymphomas: A Review of Approved and Emerging Targeted Therapies
Indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by generally slow growth kinetics and a relapsing/remitting course. Survival outcomes have improved significantly over the last two decades, but indolent B-NHLs remain incurable with progressively shortening remissions following each line of therapy [1-4]. Until recently, the management of indolent B-NHL was not disease-specific. Combinations of non-targeted cytotoxic therapies and an anti-CD20 monoclonal (mAb) antibody have been used in front-line and relapsed settings across the whole spectrum of ind...
Source: Cancer Treatment Reviews - January 4, 2023 Category: Cancer & Oncology Authors: Elizabeth Smyth, Chan Y. Cheah, John F. Seymour Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 30, 2022 Category: Cancer & Oncology Source Type: research
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review
Patients with advanced cancer of the pancreas are often treated with combination chemotherapy. When patients progress, many will be started on a different treatment, called a second-line treatment. Many drugs have been investigated as second-line treatment options for patients with pancreatic cancer. We reviewed the results of studies of second-line treatment options for advanced pancreatic cancer published since 2016 in what is called a systematic literature review. We did this because we wanted to see which second-line treatments work well and which ones work less well in patients with advanced pancreatic cancer. (Source...
Source: Cancer Treatment Reviews - December 29, 2022 Category: Cancer & Oncology Authors: Farshid Dayyani, Teresa Macarulla, Andrew Johnson, Zev A. Wainberg Source Type: research
